The numbers in the second paragraph in the section entitled, “Partial primaquine dose and unsupervised primaquine treatment” are incorrect owing to a transcription error in the final preparation of the paper.
The paragraph should read: “For all subsequent recurrences, only the first dose of the antimalarial drugs was supervised. The risk of recurrence after 6 mo of follow-up between the primary and secondary treatments did not differ significantly for patients in either the CQ arm (HR = 1.2 [95% CI 0.8–1.84], p = 0.5) or the AL arm (HR = 0.8 [95% CI 0.5–1.3], p = 0.4). However, patients were at significantly greater risk of recurrent P. vivax after the unsupervised PQ retreatment than after the partially supervised initial PQ treatment: 36.8% (95%CI 16.6%–68.3%) versus 14.7% (95% CI 8.6%–24.6%) in patients in the CQ+PQ arm (HR = 3.9 [95% CI 1.3–11.4], p = 0.014) and 48.1% (95%CI 26.5%–75.6%) versus 17.5% (95%CI 10.7%–27.8%) in patients in the AL+PQ arm (HR = 3.5 [95% CI 1.4–8.9], p = 0.008) (S2 Fig).”
- 1. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. (2017) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med 14(5): e1002299. https://doi.org/10.1371/journal.pmed.1002299 pmid:28510573
Citation: Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. (2018) Correction: Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med 15(10): e1002677. https://doi.org/10.1371/journal.pmed.1002677
Published: October 4, 2018
Copyright: © 2018 Abreha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.